EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Latent and active tuberculosis development in patients with rheumatoid arthritis receiving biologic disease-modifying antirheumatic drugs: A single-center prospective study

Binh Bui Hai, Tuan Le Anh, Phuong Nguyen Thi Thu iD, Hung Nguyen Van, Giap Vu Van, Dung Hoang Van iD

PLOS ONE · 11.01.2024 · 19 (1) · e0295048

DOI: 10.1371/journal.pone.0295048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 11.01.2024. Verfasst von Binh Bui Hai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Rheumatology, Bach Mai Hospital, Hanoi, Vietnam. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid, Biological Products, Latent Tuberculosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biologics have revolutionized the treatment of rheumatoid arthritis (RA) in recent years. However, data from clinical trials and actual clinical practice have shown that biologics currently in use may constitute a risk factor for reactivation of tuberculosis (TB) in patients with latent TB infection. Therefore, screening for latent and active TB infection is mandatory before initiating biologic therapy in patients with RA. This prospective study aimed to analyze the clinical characteristics of patients with RA receiving biologic disease-modifying antirheumatic drugs at Bach Mai Hospital, Vietnam, between 2017 and 2022, and to identify factors affecting the occurrence of active and latent TB infection among these patients. Over a 12-month follow-up period, latent TB infection was confirmed in 20% of the total 180 included patients, while 3 (1.7%) patients developed active TB (one case of pulmonary, pleural, and gluteal TB each). History of TB risk factor exposure and lack of education were significantly associated with the occurrence of active and latent TB infection, with odds ratios (95% confidence intervals [CIs]) of 1.98 (1.78; 2.2) and 1.45 (1.31; 1.6), respectively. Follow-up duration and number of X-ray, computed tomography, bronchoscopy, and sputum acid-fast bacteria examinations were identified as factors that can aid in the early diagnosis of latent TB, with odds ratios (95% CIs) of 1.00 (1; 1.01), 1.02 (1; 1.05), 1.12 (1.11; 1.2), 1.11 (1.09; 1.2), and 1.13 (1.09; 1.17), respectively. Our study showed that, in countries with high TB burden like Vietnam, latent TB infection has high prevalence among patients with RA. We also provide useful information for the screening, monitoring, and treatment of latent and active TB infection in patients with RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, RheumatoidBiological ProductsLatent TuberculosisTuberculosisHumansBiological FactorsProspective Studies

Substanzen

Antirheumatic AgentsBiological FactorsBiological Products

Autor:innen und Institutionen

  • Centre of Rheumatology, Bach Mai Hospital, Hanoi, Vietnam.
  • Department of Rheumatology and Endocrinology, Thanh Hoa Hospital, Thanh Hoa, Vietnam.
  • Pharmacy Faculty, Hai Phong University of Medicine and Pharmacy, Hai Phong, Vietnam.
  • Department of Pharmacy, Hai Phong International Hospital, Hai Phong, Vietnam.
  • Department of Internal Medicine, Hanoi Medical University, Hanoi, Vietnam.
  • Department of Internal Medicine, Hai Phong International Hospital, Hai Phong, Vietnam.

ORCID-Profile: Phuong Nguyen Thi Thu, Dung Hoang Van

Zitieren

APA

Hai, B. B., Anh, T. L., Thi Thu, P. N., Van, H. N., Van, G. V., & Van, D. H. (2024). Latent and active tuberculosis development in patients with rheumatoid arthritis receiving biologic disease-modifying antirheumatic drugs: A single-center prospective study. PLOS ONE, 19(1), e0295048. https://doi.org/10.1371/journal.pone.0295048

Vancouver

Hai BB, Anh TL, Thi Thu PN, Van HN, Van GV, Van DH. Latent and active tuberculosis development in patients with rheumatoid arthritis receiving biologic disease-modifying antirheumatic drugs: A single-center prospective study. PLOS ONE. 2024;19(1):e0295048. doi:10.1371/journal.pone.0295048

BibTeX
@article{Hai2024,
  author = {Hai, Binh Bui and Anh, Tuan Le and Thi Thu, Phuong Nguyen and Van, Hung Nguyen and Van, Giap Vu and Van, Dung Hoang},
  title = {Latent and active tuberculosis development in patients with rheumatoid arthritis receiving biologic disease-modifying antirheumatic drugs: A single-center prospective study},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {1},
  pages = {e0295048},
  doi = {10.1371/journal.pone.0295048}
}
Kostenlos starten →